Company intelligence / Profile preview

Great Bay Bio

Hong Kong / Tai Po New Town / Pak Shek Kok, Hong Kong SAR Chinagreatbay-bio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Great Bay Bio has developed and commercialized multiple AI-driven technology platforms for cell line development, media optimization, and bioprocess automation. Their technologies have been adopted by global partners to accelerate drug discovery and manufacturing processes. The company is recognized for its innovation with numerous industry awards but does not report its own clinical trial results as it primarily enables other companies' pipelines.

Modalities: Monoclonal antibodies (mAbs)Recombinant proteins
Industry: Drug Discovery Services

Partnerships

Chime Biologics (strategic alliance integrating GBB’s AI-driven ecosystem with Chime’s CDMO services)Collaboration with Prof JZ Chen at MIT Koch Institute for novel tumor antibody co-development

Beyond the preview

Go deeper on Great Bay Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Great Bay Bio.

Explore the full profile